EP2200591A2 - Controlled release pharmaceutical dosage forms of trimetazidine - Google Patents

Controlled release pharmaceutical dosage forms of trimetazidine

Info

Publication number
EP2200591A2
EP2200591A2 EP08807614A EP08807614A EP2200591A2 EP 2200591 A2 EP2200591 A2 EP 2200591A2 EP 08807614 A EP08807614 A EP 08807614A EP 08807614 A EP08807614 A EP 08807614A EP 2200591 A2 EP2200591 A2 EP 2200591A2
Authority
EP
European Patent Office
Prior art keywords
trimetazidine
dosage form
pharmaceutically acceptable
controlled release
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08807614A
Other languages
German (de)
French (fr)
Inventor
Sweta Varshney
Anant Ramesh Katkar
Kalaiselvan Ramaraju
Rajan Kumar Verma
Rajeev Singh Raghuvanshi
Himadri Sen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN1925DE2007 priority Critical
Priority to IN1226DE2008 priority
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Priority to PCT/IB2008/053679 priority patent/WO2009034541A2/en
Publication of EP2200591A2 publication Critical patent/EP2200591A2/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The present invention relates to new solid dosage forms for the controlled release of trimetazidine suitable for once-daily dosing, in which the dosage form exhibits a controlled in vitro release of trimetazidine in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours when measured using USP Apparatus I at 100 rpm, thereby decreasing the incidence and severity of burst release or dose dumping.

Description

CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORMS OF

TRIMETAZIDINE

Field of the Invention

The present invention relates to new solid pharmaceutical dosage forms for the controlled release of trimetazidine suitable for once-daily dosing.

Background of the Invention

Trimetazidine [l-(2,3,4-trimethoxybenzyl piperazine] is a 3-ketoacyl-coenzyme A thiolase inhibitor with a cytoprotective effect, which by preserving the energy metabolisms of the cell exposed to the hypoxia or ischaemia, avoids the collapse of the intracellular rate of adenosine triphosphate (ATP). Thus it ensures the functioning of the ion pumps and the sodium-potassium transmembrane flux and maintains the cellular homeostasis.

Trimetazidine dihydrochloride is used therapeutically in the long-term treatment of angina pectoris. It is freely soluble in water and has two pKa values 4.32 and 8.95. Trimetazidine dihydrochloride is administered orally in doses of 40 to 60mg daily in divided doses as an immediate release preparation. It is quickly absorbed and eliminated by the organism with plasma half-life of around 6.0 +/- 1.4 hours and Tmax of around 1.8 +/- 0.7 hours. Since it has a shorter plasma half life, in practice 20mg preparation is given twice or thrice a day in order to ensure relatively constant plasma levels. Servier had developed a modified-release dosage form containing 35mg for twice- daily administration, marketed under the brand name "VASTAREL MR". This dosage form was bioequivalent to the 20 mg conventional thrice-a-day formulation of trimetazidine hydrochloride. The modified-release formulation is based on a hydrophilic matrix that utilizes polymers which swell in contact with gastrointestinal fluids to form gels. This formulation has been covered by Servier in a European patent published as EP 1 108 424, which discloses a matrix tablet enabling prolonged release of trimetazidine comprised of cellulose derivative polymers. The formulation described releases more than 90% of the drug in-vitro within a period of 4 hours.

European patent EP 0 673 649 also assigned to Servier describes pharmaceutical compositions for the prolonged release of trimetazidine wherein prolonged release is ensured by the reservoir system. The composition is prepared by compression of the active ingredient mixture and excipient, which are then coated with an insoluble polymer.

The prior art describes the use of hydrophilic polymers for controlling the release of trimetazidine from the controlled release pharmaceutical compositions. However, for water-soluble salts such as hydrochloride salt of trimetazidine, it may result in burst release or dose dumping.

The PCT application WO 03/043610 filed by Themis Laboratories, discloses a process for manufacturing microbeads, which enable "once a day" dosing for 60 mg dose of trimetazidine dihydrochloride per unit dose. The application further provides dissolution rates at different time periods which correspond to 24 hours therapeutic blood levels. Further, it discloses the dissolution rate to be not less than 65% w/w in 6 hours.

The European patent application EP 1 195 160 filed by USV, discloses a sustained release dosage form of trimetazidine that releases more than 90% of the drug in- vitro within a period of about 6 hours to about 8 hours. The dosage form employs hydrophobic substance and a hydrocolloid for sustaining the release.

A controlled in vitro release of trimetazidine is of most importance in the context of in vivo drug profiles. Drug absorption from a solid dosage form following oral administration depends on the release of the drug substance from the drug product, the dissolution or solubilization of the drug under physiological conditions, and the permeability across the gastrointestinal tract. Because of the critical nature of the first two of these steps, in vitro dissolution may be relevant to the prediction of in vivo performance.

Therefore, taking into account the great therapeutic interest of trimetazidine, there exists a need in the state of the art for new pharmaceutical dosage forms for "once a day" dosing of trimetazidine, prepared by a simpler process that is cost-effective and yields a dosage form with pH independent release of trimetazidine for at least 16 hours without any lag period.

The present invention provides new solid pharmaceutical dosage forms for the controlled release of trimetazidine suitable for once-daily dosing, in which the dosage form exhibits a controlled in vitro release of trimetazidine in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours when measured using USP Apparatus I at 100 rpm, thereby decreasing the incidence and severity of burst release or dose dumping. The pharmaceutical dosage form of the present invention uses a cost effective and rapid operation process.

Although water-insoluble polymers have been employed as a coating polymer in reservoir systems, these systems produced a release profile where trimetazidine hydrochloride is not available for immediate absorption and pharmacological action. Other factors such as complexity of process, need for specialized equipment, incomplete release, etc. may also limit its use.

The present invention utilizes a simpler process of employing water-insoluble polymers as the matrix forming polymer. However, the water insoluble polymers, due to their nature, may result in a slower release, particularly in the beginning, leading to a lag phase. This is mainly due to less intake of aqueous medium. To avoid this, a water swellable polymer may be incorporated in the matrix which results in increased early wetting. Summary of the Invention

In one general aspect there is provided a controlled release monolithic matrix dosage form comprising:

(a) therapeutically effective amount of trimetazidine or its pharmaceutically acceptable salts, (b) one or more rate controlling polymers selected from the group consisting of a water- insoluble polymer , water- swellable polymer, and mixture thereof, and

(c) one or more pharmaceutically acceptable excipients, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours. Controlled release dosage forms of trimetazidine suitable for once-daily dosing, contain less than about lOOmg of trimetazidine.

Particularly the dosage forms contain about 50 mg to about 80 mg of trimetazidine. Particularly, controlled release dosage forms of trimetazidine suitable for once-daily dosing contain about 70 mg of trimetazidine. Controlled release dosage forms of the present invention comprise about 5 to 50% by weight of trimetazidine based upon the total weight of the dosage form.

Examples of water-insoluble rate controlling polymers include but are not limited to, one or more of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, co-polymers of acrylate or methacrylate having a low quaternary ammonium content, poly vinyl acetate, or mixtures thereof. Particularly the water- insoluble polymers are ethyl cellulose, acrylic acid polymers or a combination of the two. The water-insoluble polymers comprise about 5 to about 90% by weight of the dosage form. Particularly the water-insoluble polymers may comprise about 20 to about 60% by weight of the dosage form.

Examples of water swellable rate controlling polymers include but are not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, methylcellulose, starch, gums, alginates, acrylic acid derivatives, gelatin and polyethylene oxide. Particularly the water swellable rate controlling polymer is xanthan gum.

The water swellable polymers may comprise about 5 to about 90% by weight of the dosage form. Particularly the water swellable polymers may comprise about 7% to about 60% by weight of the dosage form.

To further control the release in the early phase and to obtain a near zero-order release profile, the highly water soluble drug trimetazidine or one of its salts is dispersed in a hydrophobic material.

In another aspect there is provided a controlled release monolithic matrix dosage form of trimetazidine comprising:

(a) therapeutically effective amount of trimetazidine or its pharmaceutically acceptable salts,

(b) at least one hydrophobic material, and

(c) one or more rate controlling polymers selected from the group consisting of a water- insoluble polymer , water- swellable polymer, and mixture thereof, wherein trimetazidine is dispersed uniformly in the hydrophobic material, and wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.

Examples of hydrophobic material include but are not limited to, one or more of fatty acids, long chain fatty alcohols, waxes, vegetable oil and glycerides of Cό-Ci8 fatty acids or mineral oil or mixtures thereof.

Particularly, the hydrophobic material comprises carnauba wax, stearic acid or mixtures thereof.

The hydrophobic materials may comprise about 5 to about 90% by weight of the dosage form. Particularly the hydrophobic materials may comprise about 20 to about 60% by weight of the dosage form.

In another aspect there is provided a process for preparing a controlled release monolithic matrix dosage form of trimetazidine comprising the steps of:

(a) blending/mixing trimetazidine and one or more rate controlling polymers with one or more pharmaceutically acceptable excipients, and

(b) compressing the blend of step (a) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.

In another aspect there is provided a process for preparing a controlled release monolithic matrix dosage form of trimetazidine comprising the steps of:

(a) granulating trimetazidine, atleast one pharmaceutically acceptable excipient and one or more rate controlling polymers,

(b) blending/mixing the material of step (a) with one or more pharmaceutically acceptable excipients, and (c) compressing the blend of step (b) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours. In one of the embodiments, the granulation is carried out by wet granulating the active and the pharmaceutically acceptable excipients with a solution or dispersion of rate controlling polymer.

In another embodiment, a part of the rate controlling polymer is added along with the active. Alernatively, the granulation is carried out by dry blending the active, the pharmaceutically acceptable excipients and the rate controlling polymers and compacting to form granules.

In another aspect there is provided a process for preparing a controlled release monolithic matrix dosage form of trimetazidine comprising the steps of: (a) dispersing trimetazidine in at least one hydrophobic material;

(b) milling the material of step (a);

(c) mixing/blending the material of step (b) with a rate controlling polymer and other excipients;

(d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.

In another aspect there is provided a process for preparing a controlled release monolithic matrix dosage form of trimetazidine comprising the steps of:

(a) dispersing trimetazidine in atleast one hydrophobic material; (b) milling the material of step (a);

(c) granulating the material of step (b) with a rate controlling polymer and other excipients;

(d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.

The active is dispersed in at least one hydrophobic material with the help of solvents or by melting the hydrophobic material slightly above its melting point and dispersing the active in it. In one of the embodiments, the granulation is carried out by wet granulating the active and the pharmaceutically acceptable excipients with a solution or dispersion of rate controlling polymer.

In another embodiment, a part of the rate controlling polymer is added along with the active. Alernatively, the granulation is carried out by dry blending the active, the pharmaceutically acceptable excipients and the rate controlling polymers and compacting to form granules.

Example of solvents used for granulation comprise methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water or mixtures thereof. The hydrophobic materials were melted at temperatures ranging from about 4O0C to about 120° C. Particularly, the hydrophobic materials were melted at a temperature range of about 60° C to about 80° C.

The controlled release dosage forms comprise one or more pharmaceutically acceptable excipients selected from one or more of binders, fillers, lubricants, glidants, coloring agents and flavoring agents.

In another embodiment, the dosage form is optionally coated with one or more layers comprising film forming agents and/or pharmaceutically acceptable excipients.

In another aspect there is provided a method of prophylactic treatment of angina pectoris comprising administering a controlled release monolithic matrix dosage form of trimetazidine, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.

The controlled release monolithic matrix dosage form of trimetazidine may be administered in combination with other cardio therapeutic agents. The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and claims.

Detailed Description of the Invention

The present invention relates to controlled release dosage forms of trimetazidine suitable for once-daily dosing, containing less than about lOOmg of trimetazidine. Preferably the dosage forms contain about 50 mg to about 80 mg of trimetazidine. Particularly, controlled release dosage forms of trimetazidine suitable for once-daily dosing contain about 70mg of trimetazidine.

Trimetazidine used herein should be understood as the base or any of its pharmaceutically acceptable salt thereof. Particularly, the salt is dihydrochloride. Controlled release dosage forms of the present invention comprise about 5 to 50% by weight of trimetazidine.

The term "controlled-release", as used herein, includes any type of controlled- release including prolonged release, sustained release, modified release and extended release.

The pharmaceutical dosage forms of the present invention can be administered orally in the form of tablets or capsules filled with pellets, beads, granules, multiparticulates, tablets or powder.

The present invention employs water insoluble polymeric matrix to control the release of highly water soluble trimetazidine. A water swellable polymer is also added to the matrix to allow the aqueous medium to penetrate the dosage form and provide a tortuous path for uniform drug release. The active is released uniformly over a period of 12 to 24 hours in a substantially linear or zero order release.

Examples of water-insoluble rate controlling polymers include but are not limited to, one or more of ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, co-polymers of acrylate or methacrylate having a low quaternary ammonium content, poly vinyl acetate, or mixtures thereof. Particularly the water- insoluble polymers are ethyl cellulose, acrylic acid polymers or a combination of the two. The water-insoluble polymers comprise about 5 to about 90% by weight of the dosage form. Particularly the water-insoluble polymers may comprise about 20 to about 60% by weight of the dosage form.

Examples of water swellable rate controlling polymers include but are not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, methylcellulose, starch, gums, alginates, acrylic acid derivatives, gelatin and polyethylene oxide. The water swellable polymers may comprise about 5 to about 90% by weight of the dosage form. Particularly the water swellable polymers may comprise about 7% to about 60% by weight of the dosage form.

The release of trimetazidine from the dosage form is further controlled in the early phase and a near zero-order release profile is obtained when the drug is dispersed in a hydrophobic material.

Examples of hydrophobic material include but are not limited to, one or more of fatty acids, long chain fatty alcohols, waxes, vegetable oil and glycerides of Cό-Ci8 fatty acids or mineral oil or mixtures thereof. The hydrophobic materials may comprise about 5 to about 90% by weight of the dosage form. Particularly the hydrophobic materials may comprise about 20 to about 60% by weight of the dosage form.

The controlled release dosage forms may further comprise one or more pharmaceutically acceptable excipients.

The pharmaceutically acceptable excipients are those known to the skilled in the art and may be selected from binders, fillers, lubricants, glidants, coloring agents and flavoring agents.

Examples of binders include, but are not limited to, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, pregelatinized starch, agar, tragacanth, sodium alginate and propylene glycol. Examples of fillers or diluents include, but are not limited to, corn starch, lactose, white sugar, sucrose, sugar compressible, sugar confectioners, glucose, sorbitol, calcium carbonate, calcium dihydrogen phosphate dihydrates, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose, fructose, kaolin, lactitol, mannitol, starch and starch pregelatinized.

Particularly, the fillers comprise microcrystalline cellulose, calcium dihydrogen phosphate dihydrate or a mixture of both.

Examples of lubricants and glidants include, but are not limited to, colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax and white beeswax.

The coloring agents and flavoring agents of the present invention may be selected from any FDA approved colors and flavors for oral use. The ingredients discussed above may be formed into dosage forms by conventional techniques, for example either by direct compression, or first compacting some of the ingredients, milling the compacts, blending with the remaining ingredients and then compressing as appropriate.

The controlled release monolithic matrix dosage forms may also be prepared using wet granulation techniques. The process may include granulation of trimetazidine and the rate controlling polymers with a solvent or granulation of trimetazidine with a solution of the polymer. The process may further include drying the granules prior to compressing into tablets.

The controlled release dosage forms of the present invention can optionally be coated with one or more layers comprising film forming agents and/or pharmaceutically acceptable excipients.

Coating may be performed by applying one or more film forming polymers with or without other pharmaceutically inert excipients. This may be done as a solution or suspensions using any conventional coating technique known in the prior art, such as spray coating in a conventional coating pan or fluidized bed processor, or dip coating.

Suitable film forming polymers include one or more of ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, waxes, methacrylic acid polymers such as Eudragit® RL and RS, and mixtures thereof. The coating can also be performed using any commercially available ready to coat preparations such as Opadry-AMB, Opadry- White, Opadry-Clear, etc. Suitable solvents used for making a solution/suspension of film forming polymer include one or more of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.

Use of a controlled release monolithic matrix dosage form of trimetazidine in the prophylactic treatment of angina pectoris is provided, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.

The controlled release monolithic matrix dosage form of trimetazidine may be administered in combination with other cardio therapeutic agents.

EXAMPLES

Examples 1, 2 & 3: Controlled release monolithic matrix dosage forms of trimetazdine dihydrochloride

Process:

1. Trimetazidine dihydrochloride, microcrystalline cellulose (High viscosity), xanthan gum & ethylcellulose (High viscosity) were mixed and granulated with ethylcellulose (Low viscosity).

2. Granules of step-1 were blended with microcrystalline cellulose (Low viscosity), carbopol, colloidal silicon dioxide and magnesium stearate.

3. Blend of step-2 was compressed into tablets.

The controlled release (CR) dosage forms prepared according to Examples 1, 2 and 3 were subjected to in vitro drug release test which utilizes the United States Pharmacopea (USP) Apparatus 1 (rotating basket) at 100 rpm with 500 ml of phosphate buffer at pH 6.8 and 37° C. The results of the in vitro drug release test are given in Table 1.

Table 1: Drug Release of Trimetazidine CR dosage forms prepared as per Examples 1, 2 and 3 in Phosphate buffer pH 6.8, 500 ml, USP 1 at 100 rpm.

Example 4: Controlled release monolithic matrix dosage form of trimetazdine dihydrochloride

Process:

1. Trimetazidine hydrochloride was dispersed in a molten mass of carnauba wax and stearic acid.

2. Dispersion of step 1 was stirred till it cooled.

3. Material of step 2 was milled and blended with ethyl cellulose; xanthan gum; microcrystalline cellulose; colloidal silicon dioxide and magnesium stearate.

4. Blend of step 3 was compressed into tablets. Example 5: Controlled release monolithic matrix dosage form of trimetazdine dihydrochloride

Process:

1. Trimetazidine hydrochloride was dispersed in a molten mass of carnauba wax and stearic acid.

2. Dispersion of step 1 was stirred till it cooled. 3. Material of step 2 was milled and blended with ethyl cellulose; xanthan gum; microcrystalline cellulose; calcium dihydrogen phosphate dihydrate; colloidal silicon dioxide and magnesium stearate.

4. Material of step 3 was compressed into tablets.

5. Tablets of step 4 were coated with the coating composition.

The controlled release (CR) dosage form prepared according to Example 5 were subjected to in vitro drug release test which utilizes the United States Pharmacopea (USP) Apparatus 1 (rotating basket) at 100 rpm with 500 ml of phosphate buffer at pH 6.8 and 37° C. The results of the in vitro drug release test are given in Table 2.

Table 2: Drug Release of Trimetazidine CR dosage form prepared as per Example 5 in Phosphate buffer pH 6.8, 500 ml, USP 1 at 100 rpm.

In vivo Bioequivalence Study

In vivo performance of a single dose of trimetazidine controlled release dosage forms as per present invention administered once daily (OD) were evaluated with respect to three doses of VASTAREL 20 mg tablets (Immediate release product of trimetazidine) administered thrice daily and two doses of VASTAREL MR 35 mg tablets (Modified release product of trimetazidine) administered twice daily under fasting and fed conditions in healthy male volunteers. Pharmacokinetic parameters Cmax (Peak serum concentration); AUCt (Area under the plasma concentration vs. time curve); and AUCinf (Area under the plasma concentration vs. time curve upto infinity) were calculated from the data obtained. The results of the study are given in Tables 3 and 4.

Table 3: Pharmacokinetic data for controlled release (CR) monolithic matrix dosage forms prepared as per present invention. Once daily vs. three doses of VASTAREL 20 mg tablets (containing trimetazidine 20 mg) administered thrice daily

Table 4: Pharmacokinetic data for controlled release controlled release monolithic matrix dosage forms prepared as per present invention. Once daily vs. two doses of VASTAREL MR 35 mg tablets (containing trimetazidine 35 mg) administered twice daily

While there has been shown and described what are the preferred embodiments of the invention, one skilled in the pharmaceutical formulation art will appreciate that various modifications in the dosage forms and process can be made with out departing from the scope of the invention as it is defined by the appended claims.

Claims

CLAIMS: 1. A controlled release monolithic matrix dosage form comprising: (a) therapeutically effective amount of trimetazidine or its pharmaceutically acceptable salts, (b) one or more rate controlling polymers selected from the group consisting of a water- insoluble polymer , water- swellable polymer, and mixture thereof, and (c) one or more pharmaceutically acceptable excipients, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
2. The dosage form of claim 1, further comprising trimetazidine or its pharmaceutically acceptable salt dispersed in at least one hydrophobic material.
3. A controlled release monolithic matrix dosage form of trimetazidine comprising: (a) therapeutically effective amount of trimetazidine or its pharmaceutically acceptable salts, (b) atleast one hydrophobic material, and (c) one or more rate controlling polymers selected from the group consisting of a water-insoluble polymer , water-swellable polymer and mixture thereof, wherein trimetazidine is dispersed uniformly in the hydrophobic material, and wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
4. The dosage form according to claims 1-3, wherein the in vitro release is measured by a drug release test which utilizes the United States Pharmacopoeia (USP) Apparatus 1 (rotating basket) at 100 rpm with 500 ml of phosphate buffer at pH 6.8 and 37° C.
5. The dosage form according to claims 1-3, wherein the water-insoluble polymer comprises ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, co-polymers of acrylate or methacrylate having a low quaternary ammonium content, poly vinyl acetate, or mixtures thereof and wherein the water-insoluble polymer comprises about 20 to about 60% by weight of the dosage form.
6. The dosage form according to claims 1-3, wherein the water swellable polymer comprises hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, methylcellulose, starch, gums, alginates, acrylic acid derivatives, gelatin and polyethylene oxide or mixtures thereof.
7. The dosage form according to claim 6, wherein the water swellable polymer is xanthan gum.
8. The dosage form according to claim 6, wherein the water swellable polymer comprises about 7% to about 60% by weight of the dosage form.
9. The dosage form according to claim 3, wherein the hydrophobic material comprises fatty acids, long chain fatty alcohols, waxes, vegetable oil and glycerides of C6- Ci8 fatty acids, mineral oil, or mixtures thereof.
10. The dosage form according to claim 9, wherein the hydrophobic material comprises carnauba wax, stearic acid, or mixtures thereof.
11. The dosage form according to claim 9, wherein the hydrophobic material comprises about 20 to about 60% by weight of the dosage form.
12. The dosage form according to claims 1-3, further comprising pharmaceutically acceptable excipients selected from one or more of fillers, binders, lubricants, glidants, coloring agents and flavoring agents.
13. A process for preparing a controlled release monolithic matrix dosage form of trimetazidine according to claim 1 comprising the steps of: (a) blending/mixing trimetazidine and one or more rate controlling polymers with one or more pharmaceutically acceptable excipients, and (b) compressing the blend of step (a) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
14. A process for preparing a controlled release monolithic matrix dosage form of trimetazidine according to claim 1 comprising the steps of: (a) granulating trimetazidine, atleast one pharmaceutically acceptable excipient and one or more rate controlling polymers, (b) blending/mixing the material of step (a) with one or more pharmaceutically acceptable excipients, and (c) compressing the blend of step (b) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
15. A process for preparing a controlled release monolithic matrix dosage form of trimetazidine according to claim 3 comprising the steps of: (a) dispersing trimetazidine in atleast one hydrophobic material; (b) milling the material of step (a); (c) mixing/blending the material of step (b) with a rate controlling polymer and other excipients; (d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
16. A process for preparing a controlled release monolithic matrix dosage form of trimetazidine according to claim 3 comprising the steps of: (a) dispersing trimetazidine in atleast one hydrophobic material; (b) milling the material of step (a); (c) granulating the material of step (b) with a rate controlling polymer and other excipients; (d) compressing the blend of step (c) into tablets; wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
17. A process of preparing a controlled release monolithic matrix dosage form of trimetazidine according to claims 15 and 16, wherein trimetazidine is dispersed in a molten mass of the hydrophobic material.
18. The dosage form according to the preceding claims, wherein the dosage form is further coated with one or more layers comprising film forming agents and/or pharmaceutically acceptable excipients.
19. Use of a controlled release monolithic matrix dosage form of trimetazidine in the prophylactic treatment of angina pectoris, wherein the dosage form exhibits in vitro release of trimetazidine or its pharmaceutically acceptable salt in phosphate buffer at pH 6.8 of not less than about 75% after 16 hours.
EP08807614A 2007-09-11 2008-09-11 Controlled release pharmaceutical dosage forms of trimetazidine Withdrawn EP2200591A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IN1925DE2007 2007-09-11
IN1226DE2008 2008-05-16
PCT/IB2008/053679 WO2009034541A2 (en) 2007-09-11 2008-09-11 Controlled release pharmaceutical dosage forms of trimetazidine

Publications (1)

Publication Number Publication Date
EP2200591A2 true EP2200591A2 (en) 2010-06-30

Family

ID=40120263

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08807614A Withdrawn EP2200591A2 (en) 2007-09-11 2008-09-11 Controlled release pharmaceutical dosage forms of trimetazidine

Country Status (2)

Country Link
EP (1) EP2200591A2 (en)
WO (1) WO2009034541A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Abuse-proofed dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Unbreakable dosage forms with delayed release
TWI454288B (en) 2008-01-25 2014-10-01 Gruenenthal Chemie Pharmaceutical dosage form
CA2723438C (en) 2008-05-09 2016-10-11 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
EP2456424B1 (en) 2009-07-22 2013-08-28 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
PE10672012A1 (en) 2009-07-22 2012-09-05 Gruenenthal Chemie Form of controlled release dosage extruded by hot melt
TR201001902A2 (en) 2010-03-12 2011-04-21 Ali Raif İlaç Sanayi Ve Ticaret A.Ş. The extended release tablet trimetazidine
EP2394644B1 (en) * 2010-05-04 2014-07-09 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Trimetazidine Formulation With Different Release Profiles
JP5933553B2 (en) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Abuse-resistant dosage form comprising an anionic polymer
KR20130097202A (en) 2010-09-02 2013-09-02 그뤼넨탈 게엠베하 Tamper resistant dosage form comprising inorganic salt
HUE034711T2 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102824644B (en) * 2012-09-13 2013-12-25 浙江诚意药业有限公司 High-stability sustained-release tablet prepared by using hydroxy propyl cellulose
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
JP6445537B2 (en) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Modified anti containing one or more particles (tamper-resistant) dosage forms
JP2017518980A (en) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Containing tapentadol, modified prevent immediate release capsule formulation
MX2016015417A (en) * 2014-05-26 2017-02-22 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping.
KR20170139158A (en) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 Immediately released and prevent the tamper-resistant dosage form extraction solvent
WO2018129045A1 (en) * 2017-01-03 2018-07-12 Saghmos Therapeutics, Inc. Methods of improving patient compliance to treat contrast-induced injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0625055B2 (en) * 1985-03-18 1994-04-06 日本ケミフア株式会社 Persistence tablet
FR2717687B1 (en) * 1994-03-24 1996-06-14 Adir pharmaceutical compositions for the prolonged release of trimetazidine after oral administration.
FR2802424B1 (en) * 1999-12-17 2002-02-15 Adir matrix tablet for the prolonged release of trimetazidine after oral administration
DE60042972D1 (en) * 2000-10-05 2009-10-29 Usv Ltd Trimetazidine pharmaceutical comprising the sustained-release and methods for preparing
FR2818549B1 (en) * 2000-12-26 2003-02-07 Servier Lab Solid thermoformable pharmaceutical composition for the controlled release of trimetazidine
HU0500382A3 (en) 2001-11-21 2008-03-28 Themis Lab Private Ltd Sustained release pharmaceutical compositions containing microbeads of trimetazidine dihydrochloride and process for producing them
FR2885807B1 (en) * 2005-05-18 2008-05-16 Mg Pharma A solid pharmaceutical sustained release composition of 1- (2,3,4-trimethoxybenzyl) piperazine, and method of preparing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009034541A2 *

Also Published As

Publication number Publication date
WO2009034541A9 (en) 2009-12-30
WO2009034541A3 (en) 2009-07-30
WO2009034541A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
JP4204783B2 (en) Levodopa / carbidopa / entacapone pharmaceutical preparations
KR101290925B1 (en) Coated tablet formulation and method
ES2427252T3 (en) Fenofibrate pharmaceutical composition having high bioavailability and process for its preparation
ES2299287B1 (en) Oral forms of administration of propiverine or pharmaceutically acceptable salts thereof with extended release of the active substance.
KR100958045B1 (en) Pharmaceutical containing 3-3-dimethylamino-1-ethyl-2-methyl-propylphenol and providing delayed release of the active ingredient
CA2343376C (en) Sustained release ranolazine formulations
JP4785847B2 (en) Pramipexole or release tablet formulation is extended including acceptable salt thereof pharmaceutical, their preparation and use thereof
US20100021542A1 (en) Extended release oral dosage composition
US4454108A (en) Prolonged-action multiple-layer tablets
US5807579A (en) Pseudoephedrine combination pharmaceutical compositions
JP4638964B2 (en) Oral pharmaceutical dosage form comprising a proton pump inhibitor and nsaid
KR100904602B1 (en) Matrix-type sustained-release preparation containing basic drug or salt thereof, and method for manufacturing the same
ES2341751T3 (en) Stable composition for oral administration of a dose of extended release, containing pseudoephedrine and desloratadine.
US6306436B1 (en) Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US8216609B2 (en) Modified release composition of highly soluble drugs
JP4969586B2 (en) Multiple unit type sustained release oral formulation and manufacturing method thereof
ES2256950T3 (en) Fast-acting painkiller.
RU2355386C2 (en) Complex medical form with controlled release for peroral introduction of medication against diabetes and method of obtainig it
KR100869039B1 (en) Nateglinide-containing preparations
US20100291217A1 (en) Pharmaceutical compositions
US20080248107A1 (en) Controlled Release Formulation
EP0221732A2 (en) Sustained release tablets
JPH11505542A (en) For administration once daily, three-phase type pharmaceutical formulation make certain and controlled release of amorphous active ingredient
AU2008212005A1 (en) Sustained release ranolazine formulations
CA2406373C (en) Controlled release paracetamol composition

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 20100412

AK Designated contracting states:

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Extension of the european patent to

Countries concerned: ALBAMKRS

17Q First examination report

Effective date: 20110713

18D Deemed to be withdrawn

Effective date: 20111124